Arie Belldegrun Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Arie Belldegrun.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Arie Belldegrun. Arie Belldegrun is Director in Talon Therapeutics, Inc. ($EMLR) and Director in Arno Therapeutics, Inc ($ARNI) and Director in Cougar Biotechnology, Inc. ($CGRB) and Chairman, President and CEO in Kite Pharma, Inc. ($KITE) and Director in UroGen Pharma Ltd. ($URGN) and in Allogene Therapeutics, Inc. ($ALLO) and Director in Allogene Therapeutics, Inc. ($ALLO) and Director in Kronos Bio, Inc. ($KRON).
Latest Insider Trading Transactions of Arie Belldegrun
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALLO, ARNI, CGRB, KITE, KRON, EMLR, URGN
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 23 2021 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | A | 24.18 | 20,600 | 498,108 | 20,600 | |
May 25 2021 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Option Exercise | M | 18.22 | 379,066 | 6,906,583 | 0 | ||
May 25 2021 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Buy | M | 18.22 | 379,066 | 6,906,583 | 583,034 | 204 K to 583 K (+185.85 %) | |
Apr 22 2021 | URGN | UroGen Pharma Ltd. | Belldegrun Arie | Director | Option Exercise | M | 5.00 | 3,241 | 16,205 | 0 | |
Apr 22 2021 | URGN | UroGen Pharma Ltd. | Belldegrun Arie | Director | Buy | M | 5.00 | 3,241 | 16,205 | 245,452 | 242.2 K to 245.5 K (+1.34 %) |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 1,304,563 | 0 | 0 | |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 650,000 | 0 | 0 | |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 228,315 | 0 | 0 | |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 173,333 | 0 | 0 | |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 1,304,563 | 0 | 0 | |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 16.15 | 253,251 | 4,090,004 | 2,315,314 | 2.1 M to 2.3 M (+12.28 %) |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 650,000 | 0 | 0 | |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 0.00 | 1,376,313 | 0 | 2,062,063 | 685.8 K to 2.1 M (+200.70 %) |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 228,315 | 0 | 0 | |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 0.00 | 685,750 | 0 | 685,750 | 0 to 685.8 K |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 173,333 | 0 | 0 | |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 0.00 | 240,872 | 0 | 679,575 | 438.7 K to 679.6 K (+54.91 %) |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 16.15 | 253,251 | 4,090,004 | 2,315,314 | 2.1 M to 2.3 M (+12.28 %) |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 0.00 | 182,866 | 0 | 438,703 | 255.8 K to 438.7 K (+71.48 %) |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 0.00 | 1,376,313 | 0 | 2,062,063 | 685.8 K to 2.1 M (+200.70 %) |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 0.00 | 685,750 | 0 | 685,750 | 0 to 685.8 K |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 0.00 | 240,872 | 0 | 679,575 | 438.7 K to 679.6 K (+54.91 %) |
Oct 16 2020 | KRON | Kronos Bio, Inc. | Belldegrun Arie | Director | Buy | C | 0.00 | 182,866 | 0 | 438,703 | 255.8 K to 438.7 K (+71.48 %) |
Jun 10 2020 | URGN | UroGen Pharma Ltd. | Belldegrun Arie | Director | Option Exercise | A | 28.24 | 10,000 | 282,400 | 10,000 | |
Jun 04 2020 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Buy | P | 47.00 | 106,382 | 4,999,954 | 1,798,163 | 1.7 M to 1.8 M (+6.29 %) | |
Jun 04 2020 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Buy | P | 47.00 | 40,000 | 1,880,000 | 40,000 | 0 to 40 K | |
Mar 20 2020 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Option Exercise | A | 18.22 | 379,066 | 6,906,583 | 379,066 | ||
Jun 05 2019 | URGN | UroGen Pharma Ltd. | Belldegrun Arie | Director | Option Exercise | A | 34.83 | 10,000 | 348,300 | 10,000 | |
Jun 05 2019 | URGN | UroGen Pharma Ltd. | Belldegrun Arie | Director | Option Exercise | A | 34.83 | 10,000 | 348,300 | 10,000 | |
May 15 2019 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Buy | J | 0.00 | 13,413 | 0 | 515,076 | 501.7 K to 515.1 K (+2.67 %) |
May 15 2019 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Sell | J | 0.00 | 598,935 | 0 | 4,791,480 | 5.4 M to 4.8 M (-11.11 %) |
Apr 30 2019 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Buy | J | 0.00 | 13,413 | 0 | 501,663 | 488.3 K to 501.7 K (+2.75 %) |
Apr 30 2019 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Sell | J | 0.00 | 598,937 | 0 | 5,390,415 | 6 M to 5.4 M (-10.00 %) |
Mar 28 2019 | URGN | UroGen Pharma Ltd. | Belldegrun Arie | Director | Option Exercise | M | 4.02 | 128,000 | 514,560 | 0 | |
Mar 28 2019 | URGN | UroGen Pharma Ltd. | Belldegrun Arie | Director | Buy | M | 4.02 | 128,000 | 514,560 | 212,211 | 84.2 K to 212.2 K (+152.00 %) |
Mar 15 2019 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Option Exercise | A | 26.89 | 195,133 | 5,247,126 | 195,133 | |
Mar 15 2019 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Grant | A | 0.00 | 115,333 | 0 | 150,333 | 35 K to 150.3 K (+329.52 %) |
Oct 17 2018 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 285,207 | 0 | 0 | |
Oct 17 2018 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 1,140,829 | 0 | 0 | |
Oct 17 2018 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Option Exercise | C | 0.00 | 27,095 | 0 | 0 | |
Oct 17 2018 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Buy | C | 0.00 | 1,497,336 | 0 | 1,497,336 | 0 to 1.5 M |
Oct 17 2018 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Buy | C | 0.00 | 5,989,352 | 0 | 5,989,352 | 0 to 6 M |
Oct 17 2018 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Buy | C | 0.00 | 142,248 | 0 | 3,710,006 | 3.6 M to 3.7 M (+3.99 %) |
Oct 17 2018 | ALLO | Allogene Therapeut ... | Belldegrun Arie | Director | Buy | P | 18.00 | 35,000 | 630,000 | 35,000 | 0 to 35 K |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 47.42 | 159,700 | 7,572,974 | 0 | |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 63.87 | 56,643 | 3,617,788 | 0 | |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 63.87 | 44,057 | 2,813,921 | 0 | |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 51.96 | 43,500 | 2,260,260 | 0 | |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | D | 51.96 | 95,700 | 4,972,572 | 0 | |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 500,000 | 90,000,000 | 0 | 500 K to 0 (-100.00 %) |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 500,000 | 90,000,000 | 0 | 500 K to 0 (-100.00 %) |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 430,190 | 77,434,200 | 0 | 430.2 K to 0 (-100.00 %) |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 159,329 | 28,679,220 | 0 | 159.3 K to 0 (-100.00 %) |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 180.00 | 1,607,750 | 289,395,000 | 0 | 1.6 M to 0 (-100.00 %) |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | D | 0.00 | 159,160 | 0 | 0 | 159.2 K to 0 (-100.00 %) |
Oct 05 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Grant | A | 0.00 | 50,000 | 0 | 159,160 | 109.2 K to 159.2 K (+45.80 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | S | 179.66 | 26,347 | 4,733,605 | 109,160 | 135.5 K to 109.2 K (-19.44 %) |
Sep 27 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Grant | A | 0.00 | 50,000 | 0 | 135,507 | 85.5 K to 135.5 K (+58.47 %) |
May 09 2017 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Buy | P | 68.57 | 17,000 | 1,165,690 | 85,507 | 68.5 K to 85.5 K (+24.81 %) |
Dec 29 2016 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | A | 47.72 | 159,700 | 7,620,884 | 159,700 | |
Dec 29 2016 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Grant | A | 0.00 | 43,800 | 0 | 68,507 | 24.7 K to 68.5 K (+177.28 %) |
Dec 29 2016 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Gift | G | 0.00 | 66,000 | 0 | 1,607,750 | 1.7 M to 1.6 M (-3.94 %) |
Dec 22 2016 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Sell | S | 50.86 | 3,493 | 177,654 | 24,707 | 28.2 K to 24.7 K (-12.39 %) |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | P | 0.44 | 357,142 | 156,250 | 357,142 | |
Aug 17 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.00 | 714,285 | 0 | 2,262,838 | 1.5 M to 2.3 M (+46.13 %) |
Apr 11 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Option Exercise | A | 0.37 | 177,256 | 65,585 | 177,256 | |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.35 | 714,285 | 250,000 | 858,094 | 143.8 K to 858.1 K (+496.69 %) |
Jan 14 2016 | ARNI | Arno Therapeutics, ... | Belldegrun Arie | Director | Buy | P | 0.35 | 1,448,062 | 506,822 | 1,548,543 | 100.5 K to 1.5 M (+1,441.13 %) |
Dec 21 2015 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Option Exercise | A | 63.87 | 100,700 | 6,431,709 | 100,700 | |
Dec 21 2015 | KITE | Kite Pharma, Inc. | Belldegrun Arie | Chairman, President ... | Grant | A | 0.00 | 28,200 | 0 | 28,200 | 0 to 28.2 K |
Mar 03 2008 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 27.00 | 4,700 | 126,900 | 64,664 | 60 K to 64.7 K (+7.84 %) |
Mar 03 2008 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 26.99 | 300 | 8,097 | 59,964 | 59.7 K to 60 K (+0.50 %) |
Dec 18 2007 | EMLR | Talon Therapeutics ... | Belldegrun Arie | Director | Option Exercise | A | 1.12 | 40,000 | 44,800 | 40,000 | |
Dec 20 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 30.50 | 15,000 | 457,500 | 59,664 | 44.7 K to 59.7 K (+33.58 %) |
Jun 19 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 23.90 | 3,700 | 88,430 | 44,664 | 41 K to 44.7 K (+9.03 %) |
Jun 13 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Option Exercise | A | 24.50 | 10,000 | 245,000 | 10,000 | |
May 10 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 21.10 | 7,100 | 149,810 | 40,964 | 33.9 K to 41 K (+20.97 %) |
Mar 09 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 18.55 | 1,000 | 18,550 | 33,864 | 32.9 K to 33.9 K (+3.04 %) |
Mar 09 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 18.85 | 500 | 9,425 | 32,864 | 32.4 K to 32.9 K (+1.54 %) |
Mar 09 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 18.40 | 5,500 | 101,200 | 32,364 | 26.9 K to 32.4 K (+20.47 %) |
Mar 09 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 18.30 | 4,000 | 73,200 | 26,864 | 22.9 K to 26.9 K (+17.49 %) |
Mar 09 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Buy | P | 18.15 | 4,000 | 72,600 | 22,864 | 18.9 K to 22.9 K (+21.20 %) |
Jan 10 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Option Exercise | A | 2.60 | 38,411 | 99,869 | 38,411 | |
Jan 10 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Option Exercise | D | 0.39 | 38,411 | 14,999 | 38,411 | |
Jan 10 2007 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Grant | A | 0.00 | 18,864 | 0 | 18,864 | 0 to 18.9 K |
Dec 18 2006 | EMLR | Talon Therapeutics ... | Belldegrun Arie | Director | Option Exercise | A | 6.82 | 40,000 | 272,800 | 40,000 | |
Sep 11 2006 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Option Exercise | A | 4.50 | 200,000 | 900,000 | 200,000 | |
Sep 11 2006 | CGRB | Cougar Biotechnolo ... | Belldegrun Arie | Director | Option Exercise | A | 4.50 | 30,000 | 135,000 | 30,000 | |
Nov 15 2005 | EMLR | Talon Therapeutics ... | Belldegrun Arie | Director | Option Exercise | A | 4.75 | 40,000 | 190,000 | 40,000 | |
Jul 18 2005 | EMLR | Talon Therapeutics ... | Belldegrun Arie | Director | Option Exercise | A | 1.65 | 20,000 | 33,000 | 20,000 | |
Jul 18 2005 | EMLR | Talon Therapeutics ... | Belldegrun Arie | Director | Option Exercise | A | 1.33 | 20,000 | 26,600 | 20,000 |
Page: 1